Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses Roman RouzierPaolo PronzatoWilliam J. Valentine Review Open access 31 May 2013 Pages: 621 - 637
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status Gaiane M. RauchHenry M. KuererWei T. Yang Review 18 June 2013 Pages: 639 - 647
CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment K. BeelenM. OpdamS. C. Linn Preclinical Study Open access 05 June 2013 Pages: 649 - 655
T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity Denise L. CecilKyong Hwa ParkMary L. Disis Preclinical study 08 June 2013 Pages: 657 - 665
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer S. MuenstS. D. SoysalW. E Gillanders Preclinical study 12 June 2013 Pages: 667 - 676
Differential characteristics of heart, liver, and brain metastatic subsets of murine breast carcinoma Nuray ErinŞule KaleAylin F. Korcum Preclinical Study 13 June 2013 Pages: 677 - 689
Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype Hui LiSara Duhachek-MuggyAnna Zolkiewska Preclinical study 16 June 2013 Pages: 691 - 703
BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence Timothy M. D’AlfonsoRyan K. van LaarSandra J. Shin Preclinical Study 18 June 2013 Pages: 705 - 715
MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2) Xuyang JiaoLin ZhaoMinjie Wei Preclinical Study 19 June 2013 Pages: 717 - 730
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism Toru HanamuraToshifumi NiwaShin-ichi Hayashi Preclinical Study 19 June 2013 Pages: 731 - 740
HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients Soo Youn BaeYoon La ChoiSeok Jin Nam Clinical trial 31 May 2013 Pages: 741 - 750
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial J. BjöhleJ. BergqvistT. Hatschek Clinical Trial 05 June 2013 Pages: 751 - 758
Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy Stefan GlückFemke de SnooGeorge Somlo Clinical trial 12 June 2013 Pages: 759 - 767
Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention Chris I. FlowersCristina O’DonoghueLaura J. Esserman Clinical Trial Open access 14 June 2013 Pages: 769 - 777
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group Hans-Joachim LückAndreas Du BoisGunter von Minckwitz Clinical trial 15 June 2013 Pages: 779 - 787
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial Lise RocaVéronique DiérasPatricia de Cremoux Clinical trial 19 June 2013 Pages: 789 - 800
Plasma enterolactone and breast cancer risk in the Nurses’ Health Study II Jing XieShelley S. TworogerA. Heather Eliassen Epidemiology 13 June 2013 Pages: 801 - 809
Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands A. Font-GonzalezL. LiuI. Soerjomataram Epidemiology 13 June 2013 Pages: 811 - 819
Breast cancer in postmenopausal women after non-melanomatous skin cancer: the Women’s Health Initiative observational study Mary PresslerCarol A. RosenbergMichael S. Simon Epidemiology 13 June 2013 Pages: 821 - 831
Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women Courtney A. GabrielNandita MitraTimothy Rebbeck Epidemiology 14 June 2013 Pages: 833 - 843
Prevalence and impact of correlative science in breast cancer phase II trials Tian ZhangAndrew SchneiderJeffrey M. Peppercorn Epidemiology 15 June 2013 Pages: 845 - 850
Moderate-to-vigorous intensity physical activity across the life course and risk of pre- and post-menopausal breast cancer Lindsay C. KobayashiIan JanssenKristan J. Aronson Epidemiology 15 June 2013 Pages: 851 - 861
A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting Gary H. LymanDavid C. DaleJeffrey Crawford Epidemiology 16 June 2013 Pages: 863 - 872
Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival Michelle R. RobertsChi-Chen HongChristine B. Ambrosone Epidemiology 16 June 2013 Pages: 873 - 885
Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model Gillian S. DiteMaryam MahmoodiJohn L. Hopper Epidemiology 18 June 2013 Pages: 887 - 896
Adherence to screening mammography among American Indian women of the northern plains Emily L. RoenMarilyn A. RoubidouxAmr S. Soliman Brief Report 09 June 2013 Pages: 897 - 905
ROCK: a resource for integrative breast cancer data analysis Saif Ur-RehmanQiong GaoMarketa Zvelebil Brief Report 12 June 2013 Pages: 907 - 921
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen Lisette BinkhorstRon H. J. MathijssenTeun van Gelder Brief Report 13 June 2013 Pages: 923 - 929
